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D espite studies suggesting unfavorable outcomes after the administration of erythrocytes,1–5 the opti-
mal transfusion strategy in surgical and critically ill patients 
remains unclear. Concerns have been raised about harmful 
effects of low hemoglobin transfusion thresholds in individu-
als less able to tolerate anemia, such as the elderly and patients 
with cardiovascular disease or cancer.6–9 previously published 
meta-analyses were inconclusive: minimizing exposure to 
allogeneic blood reduced the risk of infection, but patients 
assigned to these restrictive transfusion strategies seemed also 
at a higher risk of myocardial infarction (Mi).10,11
since variability among studies is inevitable, undertak-
ing meta-analyses generally entails some degree of het-
erogeneity, of which three different subtypes have been 
described12: (1) clinical heterogeneity, which results from 
variability in participants, interventions, or outcomes; (2) 
methodologic heterogeneity, a consequence of variability in 
study design and risk of bias; (3) statistical heterogeneity, 
What We Already Know about This Topic
•	 Although	many	 studies	 and	 some	 systematic	 reviews	 have	
examined	the	role	of	transfusion	strategies	in	patient	morbidity	
and	mortality,	 these	 have	 not	 included	 the	 role	 for	 context-
specific	(patient	characteristics	and	clinical	setting)	conditions
What This Article Tells Us That Is New
•	 In	 a	 review	of	 31	 trials	 grouped	 into	 5	 context-specific	 strata,	
restrictive	 transfusion	 strategies	 increased	 the	 risk	 of	mortality	
and	composite	morbidity	in	patients	undergoing	cardiac/vascular	
procedures	and	in	elderly	orthopedic	patients
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ABSTRACT
Background: Blood transfusions are associated with morbidity and mortality. However, restrictive thresholds could harm 
patients less able to tolerate anemia. Using a context-specific approach (according to patient characteristics and clinical settings), 
the authors conducted a systematic review to quantify the effects of transfusion strategies.
Methods: The authors searched MeDLiNe, eMBAse, CeNtRAL, and grey literature sources to November 2015 for ran-
domized controlled trials comparing restrictive versus liberal transfusion strategies applied more than 24 h in adult surgical 
or critically ill patients. Data were independently extracted. Risk ratios were calculated for 30-day complications, defined as 
inadequate oxygen supply (myocardial, cerebral, renal, mesenteric, and peripheral ischemic injury; arrhythmia; and unstable 
angina), mortality, composite of both, and infections. statistical combination followed a context-specific approach. Additional 
analyses explored transfusion protocol heterogeneity and cointerventions effects.
Results: Thirty-one trials were regrouped into five context-specific risk strata. in patients undergoing cardiac/vascular pro-
cedures, restrictive strategies seemed to increase the risk of events reflecting inadequate oxygen supply (risk ratio [RR], 
1.09; 95% Ci, 0.97 to 1.22), mortality (RR, 1.39; 95% Ci, 0.95 to 2.04), and composite events (RR, 1.12; 95% Ci, 1.01 
to 1.24—3322, 3245, and 3322 patients, respectively). similar results were found in elderly orthopedic patients (inad-
equate oxygen supply: RR, 1.41; 95% Ci, 1.03 to 1.92; mortality: RR, 1.09; 95% Ci, 0.80 to 1.49; composite outcome: 
RR, 1.24; 95% Ci, 1.00 to 1.54—3465, 3546, and 3749 patients, respectively), but not in critically ill patients. No dif-
ference was found for infections, although a protective effect may exist. Risk estimates varied with successful/unsuccessful 
transfusion protocol implementation.
Conclusions: Restrictive transfusion strategies should be applied with caution in high-risk patients undergoing major surgery. 
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which results from clinical or methodologic heterogeneity, 
or both. identifying and addressing each type of heterogene-
ity remains a key step in undertaking meta-analyses. to date, 
however, most systematic reviews on transfusion strategies 
failed to address clinical heterogeneity, thereby limiting their 
interpretation.13–16
therefore, we conducted a context-specific systematic 
review and meta-analysis of randomized controlled trials 
(RCts) investigating the effects of restrictive transfusion 
strategies in the perioperative and acute care settings. the 
rationale for a contextual approach (i.e., stratification of 
the analysis according to patient characteristics and clini-
cal settings) was based on the prespecified assumption 
that a high degree of clinical heterogeneity may hinder 
the identification of group-specific effects: pooling data 
from various patient populations (young and elderly 
patients, for instance) or from various settings (such as 
cardiac surgery and postpartum setting) may result in a 
dilution of the intervention effects. since clinical diver-
sity may also result from variability in study interven-
tions, we were also interested in the effects of different 
transfusion protocols and in the contributing role of 
cointerventions (i.e., administration of non-erythrocyte 
blood products, hemostatic agents, or intravenous fluids) 
in complication rates.
Materials and Methods
We followed the preferred Reporting items for systematic 
Reviews and Meta-Analyses guidelines.17 eligibility crite-
ria, outcomes, and methods of analysis were prespecified 
(study protocol available at: http://alfredanaesthesia.org.au/
research).
Eligibility Criteria
Only fully published reports of RCts were included. For 
duplicates or follow-up or ancillary studies, the first pub-
lished article was considered the main study.18 Crossover 
designs or studies not adequately controlled were excluded. 
trials evaluating a multiinterventional protocol were 
excluded if the effect of transfusion strategies could not be 
distinguished from the effect of other interventions. Cluster 
randomized trials were included only if methods of analysis 
allowed for clustering.19
Only trials conducted among adult patients (more than 
18 yr old) in the perioperative, emergency, or intensive care 
settings were considered. We excluded studies conducted in 
patients with sickle cell disease.
We searched for studies comparing two different labo-
ratory values (or using symptoms of anemia) to guide 
erythrocyte administration. We excluded studies applying 
transfusion strategies 24 h or less, trials using a hemodilution 
protocol, and interventions relying on preoperative autolo-
gous blood donation, since some effects (such as immuno-
modulation) were unlikely to develop,20 and this approach is 
no longer recommended.21
We were interested in studies reporting events associ-
ated with, or worsened by, anemia.5,22–28 to fully capture all 
the effects of transfusion strategies,29,30 individual outcome 
events were combined into the following categories: “inad-
equate oxygen supply” (myocardial, cerebral, renal, mesen-
teric, and peripheral ischemic injury; arrhythmia; unstable 
angina), “mortality,” and a composite category “inadequate 
oxygen supply + mortality” (see description provided in sup-
plemental Digital Content 1, http://links.lww.com/ALN/
B275, which describes outcome categories). Only events 
occurring within 30 days were retrieved because substantial 
hemoglobin recovery seems to occur within 2 months after 
surgery/intensive care unit stay.31,32 Our aim was also to 
explore the immunomodulatory effects of allogeneic blood: 
since transfusions have been associated with impaired host 
defenses,33,34 we searched for studies reporting new infec-
tions occurring within 30 days.
Data Sources and Searches
We performed a systematic electronic search in the MeD-
LiNe (Ovid), eMBAse (Ovid), and Cochrane CeNtRAL 
databases. Both MesH terms and keywords combined with 
Boolean operators were used (see strategy provided in sup-
plemental Digital Content 2, http://links.lww.com/ALN/
B276, which provides the full search strategy used in this 
systematic review). The following sources of grey literature 
were screened: OpenGrey, international Clinical trials Reg-
istry platform, Clinicaltrials.gov. Additional reports were 
identified by hand-searching bibliographies. No language or 
date restrictions were applied. The last electronic search was 
done on November 17, 2015.
Study Selection
titles and abstracts were assessed for eligibility by two inde-
pendent reviewers (Drs. Hovaguimian and Myles). Dupli-
cate publications were identified through comparison of 
reports for author names, enrolment date, setting, interven-
tion, participant number, or baseline data. Disagreements 
were resolved through discussion.
Data Extraction
Data were extracted from original reports by one reviewer 
(Dr. Hovaguimian) and entered in a form specifically 
designed for this review (see description provided in supple-
mental Digital Content 3, http://links.lww.com/ALN/B277, 
which details which information was extracted). The second 
reviewer (Dr. Myles) verified these data, and queries were 
resolved through discussion. Missing, unclear, or incom-
plete data in the original report were clarified by contacting 
authors (two provided additional data).35,36 Outcome data 
were not considered for analysis if no clarification could be 
obtained. Data from duplicates were extracted and merged 
under a unique study identification name. Data were subse-
quently entered into the Cochrane Review Manager software 
(RevMan, version 5.3.3—The Cochrane Collaboration, The 
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Nordic Cochrane Centre, Denmark, 2014) by one reviewer 
(Dr. Hovaguimian) and checked by the second reviewer 
(Dr. Myles).
Risk of Bias in Individual Studies
The risk of bias was assessed using the Cochrane “Risk of 
bias” tool, which evaluates randomization method, conceal-
ment of treatment allocation, blinding of participants and 
personnel, blinding of outcome assessor, risk of incomplete 
outcome data, risk of selective reporting, and other sources 
of bias (ethics approval, informed consent, funding, and con-
flict of interest).37 each item was rated at “low,” “unclear,” 
or “high” risk of bias. The effects of detection and attrition 
bias were specifically explored, since this may affect studies 
evaluating adverse events (Aes).38 For cluster randomized 
trials, we used specific items as recommended elsewhere.19 
Disagreements were resolved through discussion.
Measures of Effect, Data Handling, and Transformation
Dichotomous outcomes were reported as risk ratios with 
95% Cis, while continuous data were expressed as weighted 
mean differences with 95% Ci. All statistical analyses were 
performed with the Cochrane Review Manager software. 
Data handling and transformation were necessary for some 
endpoints. Composite outcome categories were obtained 
by combining individual outcome data, as performed in 
previous reports (see description provided in supple-
mental Digital Content 4, http://links.lww.com/ALN/
B278, which outlines data handling, transformation, and 
combination).10,13
Data Synthesis and Analysis
Differences between studies in terms of patient characteris-
tics and/or clinical settings (i.e., clinical diversity) may affect 
effect estimates.12 to control for these sources of heteroge-
neity, we used a prespecified context-specific approach and 
stratified the analysis by (1) patient-specific risk of devel-
oping complications (according to age, comorbidities, and 
concomitant medication); (2) setting-related risk of com-
plications (type of surgery). studies conducted in similar 
populations and settings were regrouped into risk strata (see 
description provided in supplemental Digital Content 5, 
http://links.lww.com/ALN/B279, which explains the ratio-
nale and methods used for strata generation). Meta-analyses 
were performed only if data were obtained from at least two 
studies.
to assess if our context-specific approach was sensible, we 
conducted for each outcome category a nonstratified analy-
sis (i.e., data pooling without controlling for clinical diver-
sity) and performed a test of interaction using the Cochran 
Q and Higgins I2. We considered that different population 
parameters were represented within each risk stratum when 
the Cochran Q P-value was less than 0.05 or when I2 was 
greater than 50%.12,39 When data combination was deemed 
inappropriate, a qualitative assessment was performed.
statistical heterogeneity was assessed by visual inspec-
tion of forest plots and by using the chi-square test and 
the i2 statistic. When data were heterogeneous (P < 0.1, i2 
greater than 50%), we searched for methodologic sources of 
heterogeneity.12 We used a fixed-effect model, unless overt 
clinical or residual statistical heterogeneity was present (see 
fig., supplemental Digital Content 6, http://links.lww.com/
ALN/B280, which outlines how heterogeneity assessment 
was performed).39,40
Additional Analyses
Effect of “Successful Studies.” We assumed that only stud-
ies demonstrating successful transfusion protocol imple-
mentation would reflect true intervention effects. success 
was arbitrarily defined as a statistically significant difference 
between transfusion groups in two performance indicators: 
(1) hemoglobin levels over time and (2) mean erythrocyte 
units/group. P values were assessed from original reports. We 
also explored other possible determinants of success, such 
as hemoglobin thresholds, transfusion-sparing effect, and 
adherence rates (see description provided in supplemental 
Digital Content 7, http://links.lww.com/ALN/B281, which 
outlines which indicators were used to assess successful pro-
tocol implementation).
Effect of “Cointerventions.” several routinely administered 
drugs or other management measures may participate in the 
occurrence of Ae. Thus, we assessed the effects of noneryth-
rocyte blood products (cryoprecipitate, fresh frozen plasma, 
and platelets), antifibrinolytics, clotting factor concentrates, 
and fluids administration.
Results
Study Selection
We identified 4,684 records from MeDLiNe, 858 records 
from eMBAse, and 1741 records from CeNtRAL 
(fig. 1). Other sources retrieved no additional records. Of 
these 7,283 records, 7,193 were excluded after preliminary 
screening. Of the 90 remaining reports, 53 were discarded 
because the study population was ineligible, the intervention 
was inappropriate, the design was problematic, or the study 
presented other issues (see description provided in supple-
mental Digital Content 8, http://links.lww.com/ALN/
B282, which lists excluded studies). Of 37 relevant reports, 
6 were excluded after more thorough examination: 2 were 
duplicate publications, 1 was a preliminary analysis, and 3 
were ancillary or follow-up studies of included studies.41–46 
Thus, we included 31 RCts comparing restrictive with 
liberal transfusion strategies in the perioperative or acute 
care setting.6–9,35,36,47–71
Study Characteristics
Study Design, Participants, and Setting (table 1). included 
studies were published between 1956 and 2015, and all were 
reported in the english language. A two-arm parallel design 
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was used in all trials except in a factorial 2 × 2 design investi-
gating transfusion strategies and erythropoietin administra-
tion.65 One study was a cluster randomized trial.35
trials with similar patient populations and clinical settings 
were regrouped into five risk strata: (1) patients with cardiovas-
cular disease undergoing cardiac or vascular procedures (surgery 
or catheterization—8 trials, 3,323 patients)6,47,48,51,55,60,66,67; 
(2) elderly population with varying cardiovascular dis-
ease undergoing orthopedic surgery (9 trials, 3,777 
patients)8,9,49,50,52,54,62,63,68; (3) mixed surgical and medical 
patients with varying comorbidities admitted to an acute care 
facility (emergency or intensive care unit—10 trials, 4,129 
patients)7,35,36,53,56–59,69,70; (4) younger, less comorbid popula-
tion admitted for acute traumatic brain injury or subarachnoid 
hemorrhage (2 trials, 244 patients)61,65; (5) other patients or 
settings: one conducted among anemic women in the postpar-
tum phase and one including thrombocytopenic middle-aged 
patients with hematologic cancer (2 trials, 579 patients).64,71
Intervention: Transfusion Protocol (table  2). in the first 
group, four studies failed in implementing their protocol: in 
two, the absolute difference in hemoglobin thresholds was 
only 10 g/l, the transfusion-sparing effect was less than 20%, 
and nonadherence rates in the restrictive group were more 
than or equal to 15%;47,48 in one, transfusion thresholds 
were higher in some patients of the restrictive group com-
pared to liberal67; in one, nonadherence rates, transfusion-
sparing effects, and transfusion thresholds seemed adequate, 
but the sample size was small.51
in group 2, data to assess success were lacking in one trial,63 
and three studies showed unsuccessful implementation: in 
one, the transfusion-sparing effect was less than 20%, and 
nonadherence rates in the restrictive group were more than 
or equal to 15%62; in one, the lack of standardized protocol 
in the liberal group resulted in a negative transfusion-sparing 
effect68; and in one, surgical procedures were not adequately 
balanced between groups (liberal patients were more likely 
to bleed).8
in group 3, success was unclear in two studies (“mean 
erythrocyte units” were reported per transfused patients instead 
of per strategy group).7,53 in one unsuccessful study, the trans-
fusion-sparing effect was less than 20%, and nonadherence 
rates in the liberal group were more than or equal to 15%.35
Group 4 included two studies that demonstrated success-
ful implementation but the protocols were heterogeneous: 
one study used particularly high thresholds (restrictive: 
hemoglobin 100 g/l; liberal: hemoglobin 115 g/l), while the 
other compared 70 with 100 g/l.61,65
in the last group, success was unclear in one study report-
ing negligible transfusion-sparing effects and high nonadher-
ence rates in the restrictive group.71
Risk of Bias in Included Studies
The risk of selection bias was deemed low in only 7 of 31 
included studies (see fig., supplemental Digital Content 9, 
http://links.lww.com/ALN/B283, which summarizes the 
risk of bias in included studies).7,56,58,66,68,70,71 All studies 
were at high or unclear risk of performance bias. Outcome 
assessors were blinded in 13 studies.6–8,36,49,50,54,55,58,60,61,65,71 
The risk of attrition bias was low in all studies except three: in 
two,54,67 it was not possible to assess if attrition was balanced 
between groups, and in one,64 attrition rates exceeded 20%. 
The risk of selective reporting was low in all studies, but in 
one trial, study findings were reported in three different pub-
lications without mention of other existing reports.9,41,42
Results of Individual Studies and Data Syntheses
Events Associated to or Worsened by Anemia. 
Inadequate Oxygen Supply. (see fig., supplemental Digital 
Content 10, http://links.lww.com/ALN/B284, which illus-
trates the risk of events reflecting inadequate oxygen supply.) 
in group 1, early Mi was reported in seven studies, arrhyth-
mia in five, angina in two, stroke or transient ischemic attack 
(tiA) in five, acute kidney injury in five, and mesenteric 
ischemia in one (see table, supplemental Digital Content 
11, http://links.lww.com/ALN/B285, which outlines out-
come reporting across studies). in one study, stroke/tiA 
was reported in combination with delirium and could not 
be extracted.55 Thus, data from 8 studies (3,322 patients) 
were combined6,47,48,51,55,60,66,67: in patients with cardiovas-
cular disease assigned to a restrictive strategy and undergo-
ing high-risk surgery, there was a possible increase in events 
reflecting inadequate oxygen supply (risk ratio [RR], 1.09; 
95% Ci, 0.97 to 1.22).
in group 2, early Mi was reported in five studies, arrhyth-
mia in three, stroke/tiA in five, and AKi in two (see table, 
Fig. 1. Flow diagram illustrating the study selection process. 
ICU = intensive care unit; RCT = randomized controlled trial.
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supplemental Digital Content 11, http://links.lww.com/
ALN/B285, which outlines outcome reporting across stud-
ies). Outcomes could not be extracted in one study reporting 
“neuropsychiatric complications.”68 Thus, data from 7 studies 
(3,465 patients) were combined8,49,50,52,54,63,68: in an elderly 
population undergoing orthopedic surgery, events reflecting 
inadequate oxygen supply were significantly increased in the 
restrictive group (RR, 1.41; 95% Ci, 1.03 to 1.92).
in group 3, six studies reported “inadequate oxygen” events 
(see table, supplemental Digital Content 11, http://links.lww.
com/ALN/B285, which outlines outcome reporting across 
studies).7,56,58,70 Data from one study could not be extracted, 
since events were reported as composite outcomes.56 When 
data were combined, there was no difference between groups 
(3,590 patients; RR, 0.89; 95% Ci, 0.72 to 1.09).
Among group 4 and 5 studies, only one study reported 
the incidence of stroke.61 in this trial, patients with sub-
arachnoid hemorrhage at risk of cerebral vasospasm were 
allocated to high transfusion thresholds. There was no dif-
ference between groups (RR, 1.36; 95% Ci, 0.59 to 3.15).
Early Mortality. (see fig., supplemental Digital Content 
12, http://links.lww.com/ALN/B286, which illustrates the 
risk of early mortality.) Most group 1 to 3 studies reported 
early mortality (see table, supplemental Digital Content 
11, http://links.lww.com/ALN/B285, which outlines out-
come reporting across studies). When data were combined, 
there was a possible increase in events when a restrictive 
strategy was applied in group 1 (RR, 1.39; 95% Ci, 0.95 
to 2.04—7 studies, 3,245 patients)6,47,48,51,55,60,66 but not in 
group 2 (RR, 1.09; 95% Ci, 0.80 to 1.49—7 studies, 3,546 
patients)8,9,49,50,54,63,68 or group 3 (RR, 0.94; 95% Ci, 0.73 
to 1.20—7 studies, 2,894 patients).7,35,36,56–59 Mortality was 
not reported in groups 4 and 5.
Composite Events “Inadequate Oxygen Supply + Mortality” 
(fig. 2)
The risk of events was significantly increased when patients 
were assigned to a restrictive transfusion strategy in group 
1 (RR, 1.12; 95% Ci, 1.01 to 1.24—8 studies, 3,322 
patients)6,47,48,51,55,60,66,67 and group 2 (RR, 1.24; 95% Ci, 
1.00 to 1.54—8 studies, 3,749 patients)8,9,49,50,52,54,63,68 but 
not in group 3 (RR, 0.90; 95% Ci, 0.74 to 1.10—8 studies, 
3,762 patients).7,35,36,56–59,70 Data in groups 4 and 5 were too 
scarce to allow statistical combination.
Immunomodulatory Effects of Allogeneic Blood 
Transfusions (fig. 3)
The incidence of infections was reported in the majority of 
included studies (see table, supplemental Digital Content 11, 
http://links.lww.com/ALN/B285, which outlines outcome 
reporting across studies). in groups 1 and 3, no difference was 
found (group 1: RR, 1.11; 95% Ci, 0.94 to 1.31—6 stud-
ies, 3,141 patients6,47,55,60,66,67; group 3: RR, 0.99; 95% Ci, 
0.85 to 1.17—5 studies, 2,616 patients7,35,56,59,70). in group 
2, patients assigned to a restrictive policy seemed to have less 
septic events (RR, 0.75; 95% Ci, 0.53 to 1.04—9 studies, 
3,815 patients).8,9,49,50,52,54,62,63,68 in group 4, both studies 
reported the incidence of infection, but transfusion protocols 
were deemed too heterogeneous for statistical combination. 
When individually assessed, no difference was found (RR, 
0.77; 95% Ci, 0.51 to 1.1665; RR, 0.91; 95% Ci, 0.14 to 
5.9261). Finally, in a study conducted in the postpartum set-
ting, there was no difference between groups (RR, 1.08; 95% 
Ci, 0.63 to 1.87).64
We found significant interaction between risk strata, thereby 
indicating that our context-specific approach was appropriate 
(inadequate oxygen supply: Cochran Q P = 0.003, i2 = 82.7%; 
early mortality: P = 0.11 but i2 = 54.2%; composite outcome: 
P = 0.0007, i2 = 86.1%; infections: P = 0.04, i2 = 69.1%). Data 
pooling without controlling for clinical heterogeneity (i.e., no 
context-specific approach) resulted in a dilution of the inter-
vention effect (inadequate oxygen supply: RR, 1.02; 95% Ci, 
0.94 to 1.11; early mortality: RR, 1.00; 95% Ci, 0.89 to 1.12; 
composite outcome: RR, 1.01; 95% Ci, 0.95 to 1.08; infec-
tions: RR, 1.97; 95% Ci, 0.89 to 1.07).
Additional Analyses
The effect of successful protocol implementation on the 
risk of Ae was explored by excluding unsuccessful studies 
from each analysis (see table, supplemental Digital Con-
tent 13, http://links.lww.com/ALN/B287, which outlines 
how risk estimates varied according to successful protocol 
implementation). in group 1, risk estimates increased fur-
ther away from the null: patients in the restrictive group 
seemed to have more events reflecting inadequate oxygen 
supply (RR, 1.12; 95% Ci, 0.99 to 1.27), a 59% increase 
in mortality (RR, 1.59; 95% Ci, 1.04 to 2.44) and a sig-
nificant increase in the composite outcome (RR, 1.16; 
95% Ci, 1.03 to 1.31). However, these findings were not 
reproducible for groups 2 and 3: risk estimates decreased 
toward the null or further in favor of a restrictive strategy. 
The effect of successful implementation on infections was 
inconsistent.
We also explored the effect of cointerventions on the risk 
of Ae, but data were scarce and comparison across studies 
was difficult (see table, supplemental Digital Content 14, 
http://links.lww.com/ALN/B288, which illustrates coin-
terventions across studies). The use of clotting factor con-
centrates or antifibrinolytics was reported in three cardiac 
and one orthopedic surgery studies.55,60,62,66 Their adminis-
tration was well balanced between transfusion groups. The 
use of cryoprecipitate, fresh frozen plasma, and platelets was 
reported in four,35,55,60,66 eight,35,52,55,58,60,62,66,70 and seven 
studies,35,55,58,60,66,70,71 respectively. Overall, the adminis-
tration of blood products was similar between transfusion 
groups (cryoprecipitate: RR, 0.99; 95% Ci, 0.77 to 1.27; 
fresh frozen plasma: RR, 0.89; 95% Ci, 0.75 to 1.04); plate-
let therapy: RR, 0.95; 95% Ci, 0.81 to 1.12), but compared 
to others, patients undergoing cardiac surgery were more 
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systematically exposed to nonerythrocyte blood products. 
Finally, 10 studies reported intravenous fluid usage: in only 
three, unbalanced administration was found.52,57,62
exploring the effect of studies at high or unclear risk of 
detection and attrition bias did not yield clinically meaning-
ful results: because of the small remaining number of studies, 
95% Ci was large and risk estimates varied only mildly (data 
not shown).
Discussion
in this context-specific systematic review, we found that 
restrictive transfusion strategies were associated with an 
increased risk of complications in situations combining high-
risk patients with major surgery. Those with cardiovascular 
disease undergoing cardiac or vascular procedures seemed 
to have more events reflecting inadequate oxygen supply, 
higher mortality rates, or both. in the elderly orthopedic 
Fig. 2. Forest plots illustrating the risk of composite events. For Jairath et al.35 and Walsh et al.,36 data were obtained by contact-
ing the authors. Composite events: myocardial infarction, arrhythmia, unstable angina, stroke, acute kidney injury, mesenteric 
ischemia, peripheral ischemia, and mortality (occurring within 30 days); group 1 studies: patients with cardiovascular disease 
undergoing cardiac or vascular procedures (surgery or catheterization); group 2 studies: elderly patients undergoing orthopedic 
surgery; group 3 studies: mixed surgical/medical patient population admitted to an acute care facility (emergency or intensive 
care unit). M-H = Mantel-Haenszel data analysis.
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population, a restrictive policy led to a 40% increase in 
ischemic events or AKi.
These findings were consistent with physiologic studies 
suggesting that multiple perioperative factors may under-
mine normal compensatory responses to anemia72,73: car-
diac dysfunction (induced by anesthetic drugs or surgical 
trauma), vasoconstriction (due to endogenous or exogenous 
catecholamines), or postoperative hypoventilation (due 
to pain or residual effects of anesthetics) may compromise 
adequate oxygen delivery to vital organs. in normal condi-
tions, systemic oxygen delivery largely exceeds oxygen con-
sumption, resulting in a positive oxygen reserve.73 in patients 
having a preexisting low reserve, however, the combination 
of acute anemia with impaired compensatory responses may 
induce a state of oxygen supply dependency, resulting in aci-
dosis and organ failure. in this particular situation, admin-
istrating erythrocyte could restore the oxygen reserve by 
increasing blood oxygen content and tissue oxygenation.73
surprisingly, no evidence of harm was found when 
restrictive strategies were applied in critically ill patients, 
although similar impairment of compensatory responses 
was expected. One explanation might be the heterogeneity 
in oxygen reserve among this mixed population: medical 
patients might be at lower risk of oxygen supply dependency 
than their surgical counterparts, who have the additional 
burden of surgery, pain, and recovery from anesthesia.
Fig. 3. Forest plots illustrating the risk of infection. Group 1 studies: patients with cardiovascular disease undergoing cardiac or 
vascular procedures (surgery or catheterization); group 2 studies: elderly patients undergoing orthopedic surgery; group 3 studies: 
mixed surgical/medical patient population admitted to an acute care facility (emergency or intensive care unit).  M-H = Mantel-
Haenszel data analysis.
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When we excluded studies showing unsuccessful pro-
tocol implementation, effect estimates differed across 
risk strata. While harm was more pronounced in patients 
undergoing cardiac or vascular procedures, it decreased 
toward the null in those undergoing orthopedic surgery. 
two reasons may account for this: first, cardiac patients 
were probably more likely to enter a state of oxygen supply 
dependency (due to the combination of advanced cardio-
vascular disease and high-risk surgery) than the orthope-
dic population, where ischemic heart disease ranged from 
10 to 45%. second, cardiac patients might have been 
exposed to context-specific factors increasing their risk of 
Ae: antifibrinolytics and clotting factor concentrates were 
more systematically administered in this population, while 
this was rarely reported in orthopedic patients. Although 
tranexamic acid seems safe in trauma patients,74 the throm-
bogenic potential of other hemostatic agents in nontrauma 
settings remains unclear.75–77 Thus, the combination of a 
restrictive transfusion strategy and highly thrombogenic 
drugs in patients with advanced cardiovascular disease 
might be particularly unfavorable.
Our analysis of the risk of infection remained inconclu-
sive. Although there was a possible reduction in septic events 
in orthopedic patients assigned to a restrictive strategy, effect 
estimates differed widely across risk strata: the benefit of 
reduced exposure to allogeneic blood was less clear in car-
diac patients, which is consistent with a previously published 
meta-analysis.10 One reason might be that immune response 
impairment was more pronounced in these patients: in our 
analysis, the cardiac surgery population was more likely to 
receive nonerythrocyte allogeneic blood products (such as 
platelets or fresh frozen plasma), which are also known to 
have immunomodulatory effects.33,78–80 Alternatively, car-
diac surgery itself might induce particularly high levels of 
perioperative stress, which has also been found to interfere 
with immune responses.22,81–83
Our systematic review differs from others in many 
aspects. First, in most previous meta-analyses, data were 
combined despite high clinical heterogeneity,10,13,14,16 which 
may hinder the identification of group-specific effects. We 
addressed this methodologic limitation by performing a 
context-specific analysis, using strict criteria for risk-strata 
generation and subsequent data pooling. We were eventu-
ally able to show that indiscriminate data combination (i.e., 
performing analyses without controlling for clinical diver-
sity) resulted in a dilution of the intervention effects. Fur-
thermore, to fully explore the impact of clinical diversity, 
the issue of transfusion protocol variability was examined 
using two performance indicators and exploring three dif-
ferent determinants of success. One other meta-analysis 
investigated protocol diversity, but only hemoglobin thresh-
olds were explored.10 Additionally, our review was the first 
to assess the role of cointerventions: we were able to show 
that in some patients, the combination of restrictive transfu-
sion policies and thrombogenic drugs could be particularly 
detrimental; we also identified a possible effect of noneryth-
rocyte blood products and of perioperative stressors on the 
risk of infection.
This review has some limitations. First, although strict 
criteria were used to handle unclear/missing outcome data, 
outcome reporting and definitions varied across studies, and 
so this may result in residual clinical diversity. However, a 
certain degree of heterogeneity is desirable to ensure wide 
applicability of the findings. second, in order to capture 
the full spectrum of effects related to transfusion strate-
gies and to improve statistical precision, we used arbitrarily 
defined outcome categories. However, although endpoints 
combination might be biologically well founded, individual 
components may differ in clinical importance, and our cat-
egories may have failed to reflect endpoints truly relevant 
for patients.30 Third, in some risk strata, large studies having 
high event rates appeared to dominate the analysis, but the 
risk of a small-study effect was deemed low: we used the 
Mantel-Haenszel method to account for smaller studies and 
addressed thoroughly all sources of clinical and methodo-
logic diversity. it seems therefore unlikely that our findings 
derive solely from the effect of larger studies. Fourth, our 
assessment of methodologic heterogeneity (detection and 
attrition bias) was hampered by the scarcity of data. The 
same problem was encountered with data on cointerven-
tions, which reduced our ability to fully explore their role in 
the occurrence of complications. Finally, indicators of suc-
cessful protocol implementation were arbitrarily defined; 
using a different model might have yielded other results.
This analysis provided clear evidence that the decision 
to transfuse (or not transfuse) requires more than a “one-
size-fits-all” approach. As highlighted recently,84–86 the iden-
tification of populations at higher risk of oxygen supply 
dependency who might particularly benefit from erythro-
cyte administration remains a real challenge. New transfu-
sion algorithms should aim to integrate additional clinical 
parameters, such as patient comorbidities, particular set-
tings, or oxygen reserve estimates.73 We recommend that 
future trials systematically collect and report data regarding 
the use of nonerythrocyte blood products, antifibrinolytics, 
and clotting factor concentrates, since their role in the risk 
of Ae remains unclear.
Conclusion
This meta-analysis suggests that the use of restrictive trans-
fusion strategies might be detrimental in high-risk patients 
undergoing major surgery. Further research is needed to 
evaluate the contributing role of cointerventions in the 
occurrence of complications.
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